Low-dose pembrolizumab induced remission in patients with refractory classical Hodgkin lymphoma-Reference-Cited by-同舟云学术

Low-dose pembrolizumab induced remission in patients with refractory classical Hodgkin lymphoma

Published:2016-01-15 Issue:1 Volume:176 Page:131-132
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Kwong Yok-Lam¹,Lopes David²,Khong Pek-Lan³

Affiliation:

1. Department of Medicine; Queen Mary Hospital; Hong Kong China

2. Serviço de Hematologia; Centro Hospitalar Conde De S. Januario; Macau China

3. Department of Diagnostic Radiology; Queen Mary Hospital; Hong Kong China

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13920/fullpdf

Reference3 articles.

1. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma;Ansell;New England Journal of Medicine,2015

2. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical hodgkin lymphoma after Brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013);Moskowitz;Blood (ASH Annual Meeting Abstracts),2014

3. Refractory hodgkin lymphoma;Tresckow;Current Opinion in Oncology,2013

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course;Frontiers in Oncology;2022-06-20

2. Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation;The Journal of Clinical Pharmacology;2022-01-05

3. Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4);Signal Transduction and Targeted Therapy;2021-10-27

4. Combined immune checkpoint blockade and radiotherapy induces durable remission in relapsed natural killer/T-cell lymphoma: a case report and review of the literature;Journal of Medical Case Reports;2021-04-30

5. The Right Dose: From Phase I to Clinical Practice;American Society of Clinical Oncology Educational Book;2021-03